AUCKLAND, New Zealand, Jan. 23, 2019 (GLOBE NEWSWIRE) -- Leading global hemp CBD company Elixinol, has announced its entry into the New Zealand marketplace, offering its comprehensive range of cannabidiol (CBD) products to the NZ public on a prescription basis via the elixinol.com website.
Colorado-based Elixinol is a wholly owned subsidiary of Australian-headquartered Elixinol Global Limited (“EXL”) (ASX: EXL; OTCQX: ELLXF) and has launched in New Zealand following the December 2018 passage of New Zealand’s Misuse of Drugs (Medicinal Cannabis) Amendment Act. The Act classifies CBD with low levels of THC (the principal psychoactive constituent of cannabis) as prescription medicine and removes CBD as a Class B1 controlled drug. The Act recognizes CBD as a substance with “therapeutic value with little or no psychoactive properties”.
Individual customers looking for assistance in getting CBD are now able to import up to a three month supply of Elixinol’s CBD products, provided those products meet the medicine guidelines set forth in NZ, and enjoy the therapeutic benefits long associated with CBD. Patients in New Zealand can also enter or leave New Zealand with up to three months’ supply of CBD with evidence of prescription.
Elixinol branded capsules, topicals, and all tinctures including liposomes meet the required standard for import into New Zealand. Elixinol has already begun to receive prescriptions and is happy to announce it has just successfully shipped its first product into the New Zealand market.
“As a company which meets and exceeds quality and import standards in 41 different countries, we welcome the opportunity to serve the people of New Zealand with premium quality CBD,” said Gabriel Ettenson, Elixinol President.
“For years now, we have been receiving inquiries from people in New Zealand who want to utilise CBD for their therapeutic purposes, but until now we’ve been unable to assist,” he continued.
People interested in purchasing Elixinol CBD products should visit their GP and request the supporting material needed. They will then be able to order the products directly from the elixinol.com website.
Paul Benhaim, CEO of parent company EXL, commented, “Over the past few weeks, we have seen a groundswell of change in legislation related to cannabidiol. The US Farm Bill was passed in December, and through that process, CBD was de-scheduled from the Controlled Substances Act. Now, this change in New Zealand enables Elixinol to ship CBD to patients who have been requesting it for years. We are delighted to be one of the first companies to supply New Zealand patients with the range our US customers have been benefiting from for years.”
Colorado-based Elixinol, co-founded by Paul Benhaim, hemp entrepreneur since 1991, is widely regarded as one of the most influential CBD brands in the world. With a proven track record of growing and extracting premium-quality hemp, Elixinol is one of the few CBD hemp extract brands with complete seed-to-sale control over its products. Elixinol also conducts rigorous third-party laboratory testing and quality control. Elixinol distributes hemp-derived CBD products in 41 countries globally including North and South America, throughout Europe, Asia, and the Pacific Region under its own label as well as bulk CBD and wholesale CBD. Elixinol’s Australia-headquartered parent company EXL (elixinolglobal.com) is publicly traded on the Australian Securities Exchange (ASX) and on the U.S. OTC (ASX:EXL, OTCQX: ELLXF). More information is available at Elixinol.com.
+1 844-804-3504 ext 420
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/d042013a-470f-409e-ae37-ca024a8d71f8